Table 2.
Studies regarding adjuvant treatment for older patients diagnosed with colorectal cancer.
| Author/study | Type of study | No. of patients | No. of older patients (%)/ age cutoff (years) |
Endpoints | Outcomes |
|---|---|---|---|---|---|
| Tournigand et al. [2012] | MOSAIQ subgroup analysis for stage II disease and older patients | 2246 |
315 (14%)/ 70(<76) |
FL versus FOLFOX4: (i) DFS (ii) OS |
(i) HR 0.93 (95% CI 0.64–1.35, p = 0.73) (ii) HR 1.10 (95% CI 0.73–1.65, p = 0.661) |
|
Sannof et al. [2012a] |
Database analysis, retrospective, (SEER-Medicare, CanCONS, NCCN) |
5489 |
5489 (100%)/ 75 |
OS in stage III: (i) CT versus no CT (ii) oxaliplatin-based treatment versus nonoxaliplatin regimens |
(i) HR 0.60 (95% CI 0.53–0.68) (ii) SEER-Medicare: HR 0.84( 95% CI 0.69–1.04) NYSCR-Medicare: HR 0.82 (95% CI 0.51–1.33) |
| McCleary et al. [2013] | ACCENT group analysis in stage II/III |
14,528 | 2575 (21.5%)/ 70 |
FU versus combination regimens: DFS, OS,TTR in older (i) and younger (ii) patients |
(i) DFS: HR: 1.05 (95% CI 0.94–1.19), p = 0.09 OS: HR 1.08 (95% CI, 0.95 to 1.23), p = 0.05 TTR: HR 1.06 (95% CI 0.93–1.22), p = 0.36 (ii) DFS: HR 0.89 (95% CI 0.80–0.99), p = 0.001 TTR: HR 0.88 (95% CI, 0.79–0.98), p = 0.02 OS: HR 1.08 (95% CI 0.95–1.23)*, p = 0.04 |
*
The benefit of oxaliplatin addition is restricted to patients aged less than 70 years for OS. Oxaliplatin may benefit a subset of older patients in terms of DFS.
CI, confidence interval; CT, chemotherapy; fu, fluoropyrimidines; DFS, disease-free survival; HR, hazard ratio; OS, overall survival; TTR, time to recurrence.